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Summary: The blood plasma concentration of pseudouridine was estimated in 104 healthy adult subjects, and
108 patients suffering from malignant proliferative diseases. The HPLC method for simultaneous determination
of pseudouridine and creatinine was applied.
The average physiological concentration of pseudouridine in blood plasma was 2.43 ± 0.97 μπιοί -I"1 or
29.15 + 7.40 mmol · mol"1 creatinine. The physiological urinary excretion of pseudouridine was 14.32 ± 5.20
μπιοί -24h"1 · kg~°·75 or 19.60 + 5.22 mmol -mol"1 creatinine. Renal clearance of pseudouridine and
endogenous creatinine were 4.04 + 0.99 and 5.50 ± 1.46ml -kg"075, respectively. A positive correlation
(r = 0.55, P < 0.01) was found between age (in the range 20 — 92 years) and blood plasma pseudouridine
concentration (μιηοΐ · I"1). By expressing plasma pseudouridine in relation to plasma creatinine, the apparent
influence of non-metabolic factors (age, renal insufficiency, blood dilution) on the plasma pseudouridine
concentration were largely excluded.
Among haematological proliferative diseases the highest values of plasma pseudouridine concentrations were
observed in chronic lymphocytic leukaemia (8.19 μπιοί-I"1; 54.9 mmol -mol""1 creatinine) and multiple
myeloma (7.02 μπιοί · I"1; 52.5 mmol · mol~J creatinine). In multiple myeloma, but not in chronic lymphocytic
leukaemia, the plasma pseudouridine concentration depended on the clinical stage. A lower, but still significant
response in non^Hodgkin's lymphoma was noted (4.03 μπιοί · I"1; 40.88 mmol · mol"1 creatinine).
A significant increase of the plasma pseudouridine concentration was characteristic of adenocarcinomas of
the large intestine, and it occurred in the early stages of malignant growth. In patients with lung cancer the
plasma pseudouridine concentration was elevated only in advanced cases with metastases. The increased
pseudouridine concentration was evident in all examined cancers of the urogenital system: cancer of the
urinary bladder, cancer of the kidney, cancer of the prostate, and cancer of the testis.
It is concluded that the determination of pseudouridine in blood plasma, particularly in relation to creatinine,
is a valuable biochemical m rker of accelerated turnover rate of nucleic acids associated with neoplastic
growth.
') This study was supported by a grant from the Ministry of National Education.
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Introduction
Malignant growth is accompanied by a rapid turnover
of nucleic acids. Nucleic acid turnover may be eval-
uated by measuring its synthesis as well as degrada-
tion rate. RNA molecules contain both nucleosides
and modified nucleosides formed post-transcription-
ally by the action of modifying enzymes. In contrast
to nucleosides, most of the modified RNA catabolites
are not reutilized in nucleotide synthesis by salvage
pathways, nor are they further degraded. Modified
nucleosides released from RNA molecules in the cell
appear in extracellular fluid, as well as blood plasma,
and they are excreted in urine, some of them quan-
titatively (1, 2). The measurement of urinary excretion
of pseudouridine, 7-methylguanine, and N2,N2-di-
methyl-guanosine was used to assess whole-body
turnover of rRNA, mRNA, and tRNA in preterm
infants and adults (3, 4). Pseudouridine is generally
excreted in concentrations of 10 to 100 times that of
other nucleosides, both in healthy subjects and cancer
patients (5, 6). The source of pseudouridine detected
in urine is whole-body catabolism of tRNA and
rRNA (3, 4). Among several modified nucleosides
tested, pseudouridine is the compound of choice for
investigation in the follow up of neoplastic disease
(5). There is a considerable number of publications
concerning changes in urinary pseudouridine excre-
tion as a response to malignant growth (6 —14). There
is much less information about changes in blood
plasma concentrations of pseudouridine, which is 100
times lower than in urine, although it can still be
determined precisely with HPLC techniques (15-18).
Advantages of pseudouridine as a marker of RNA
turnover rate in comparison with other modified nu-


































cleosides are its approximately 100-fold greater con-
centration in blood plasma, and its lesser variability
attributable to the renal clearance rate, sex-related
differences, genetic influences or environmental con-
ditions (19). There are only a'few reports indicating
the elevation of serum pseudouridine concentrations
in patients suffering from neoplastic diseases (5, 17,
20, 21).
The present experiment was undertaken to extend the
above studies and to estimate blood plasma pseu-
douridine concentrations in adult healthy subjects of




Observations were performed on 212 individuals. The control
group consisted of 104 healthy volunteers (72 male and 32
female) aged between 20 and 92. The groups with haematolog-




Fig. 1. HPLC chromatogram of purines and pyrimidines in
blood plasma of a patient with adenocarcinoma of the
sigmoid, and metastases in the urinary bladder. Com-
pounds: 3.8 min — uric aci^ 4.9 min — creatinine, 5.7
min — pseudouridine, 9.1 rain — hypoxanthine, 10 min
— xanthine, 12.4 min — uridine.
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Sample preparat ion and analytical procedure
Peripheral blood (2 ml) was drawn into a heparinized syringe
prior to the morning meal. Immediately after sampling, whole
blood was centrifuged at 2500 g for 10 min at 4 °C. Two volumes
of ice-cold fresh trichloroacetic acid solution (80 g/1) were added
to the blood plasma, and the resulting precipitate removed by
centrifugation. The supernatant was then extracted three times
with 1.5 volumes of water-saturated diethyl ether to remove
the trichioroacetic acid. The aqueous layer was passed through
a 0.45 μηι Millipore filter prior to analysis.
In order to calculate the rate of urinary pseudouridine excretion
and the renal clearance of this nucleoside under physiological
conditions, twenty-four hour collection of urine was performed
in 30 healthy individuals. Urine samples were purified using
Cig SEP-PAK Waters Associates cartridges.
Pseudouridine and creatinine concentrations were determined
according to the method described by Simmonds & Harkness
(16). High performance liquid chromatography (HPLC) was
performed with an isocratic liquid Chromatograph "Beckman
330" using an ultrasphere Altex column ODS 5 μηι, 4.6 · 250
mm, RP-18 cartridge precolumn (4.6 · 30 mm) and RP-18 guard
cartridge (3.2 · 15 mm) — Pierce. The absorbance was measured
by a UV detector "Beckman 153" equipped with a 254 nm
filter. For registration and integration of results, an integrator-
recorder "Shimadzu R-R3A" was used. The mobile phase was
0.01 mol -I""1 potassium dihydrogen phosphate (pH 5.9) con-
taining 10 ml/1 methanol, at a flow rate of 1 ml · min"1. An
example of the blood plasma chromatogram of purine and
pyrirnidine compounds is presented in figure 1.
Statistical analysis
All data were stored in a database using a dBase3p programme,
then transferred to a STATGRAPH program for graphic and
statistical evaluation.
Results
The relationship between age and plasma pseudouri-
dine concentration in 104 healthy adults is presented
in figure 2. There was a statistically significant positive
correlation between age (in the range of 20 and 92
years of age) and pseudouridine concentration in
blood plasma (μπιοί -I"1)· The average pseudouridine
concentration in both males and females was 2.35 and
2.61 μιηοΐ · I""1 (differences non-significant), at the
average ages of 30 and 58, respectively. The correla-
Tab. 2. Blood plasma and urinary pseudouridine concentration
in healthy subjects.
20 40 60 80
Age [years!
100
Fig. 2. The relationship between age and blood plasma pseu-
douridine concentration (μπιοί ·1-ι) in 104 healthy
adults; r = 0.55, P ̂  0.01; ο - female, # — male




mmol · mol""1 creatinine
Urinary pseudouridine excretion
μηίοΐ · 24 h · kg'0·75
mmol · mol"1 creatinine
Renal pseudouridine clearance
ml · min"1 · kg'0·75
Renal creatinine clearance*





30 14.32 ± 5.20
30 19.60 ± 5.22
30 4.04 ± 0.99
30 5.50 ± 1.46
* glomerular filtration rate
tion coefficient of age vs pseudouridine was lowered
(r = 0.26) when pseudouridine concentration was cal-
culated per unit of plasma creatinine (mmol · mol"1
creatinine).
Average values of plasma pseudouridine concentra-
tion, rate of urinary excretion and renal clearance of
pseudouridine under physiological conditions are pre-
sented in table 2. The ratio of pseudouridine to cre-
atinine was higher in blood plasma than in urine,
which is consistent with lower values of renal pseu-
douridine clearance when compared with clearance of
endogenous creatinine.
Among lymphoproliferative diseases the highest val-
ues of blood plasma pseudouridine concentrations
were observed in chronic lymphocytic leukaemia (8.19
μπιοί -I"1; 54.9 mmol - mol"1 creatinine) and multiple
myeloma (7.02 μηιοί · I"1; 52.2 mmol · mol"1 creati-































Multiple Chronic Non- Hodgkin's
myeloma lymphocytic Hodgkin's disease
leukaemia lymphoma
Fig. 3. Blood plasma concentration of pseudouridine in pa-
tients with haematological proliferative diseases in early
(open circles) and advanced (closed circles) stages. Ad-
vanced stages are considered as: stage III in multiple
myeloma (23), stages II, III, IV in chronic lymphocytic
leukaemia (22), stages III, IV in i\on-Hodgkin*s lym-
phoma (24), stages III, IV in Hodgkin's disease (24).
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the plasma of patients with chronic lymphocytic leuk-
aemia was independent of the stage of the disease,
i. e. it was elevated to the same extent both in early
stages (0, I) and advanced stages (II, III, arid IV) of
leukaemia (clinical classification according to Rai et
al. (22)). In the case of multiple myeloma the lowest
concentration of pseudouridine was observed in 2
patients with remission and 2 patients with stage IA,
but the highest concentration was in 3 patients with
stage IIIB (clinical classification according to Dune &
Salmon (23)). Non-Hodgkirfs lymphoma was respon-
sible for a significant increase of the mean plasma
pseudouridine concentration (4.03 μπιοί -I""1 40.88
mmol · mol~J creatinine) which was seen only in ad-
vanced cases (stage III and IV - according to Ann
Arbor clinical staging classification (24)). No signifi-
cant response was observed in patients with Hodgkin's
disease (3.08 μιηοΐ -I"1; 36.4 mmol -mol""1 creati-
nine).
In all examined cancers average values were signifi-
cantly higher compared with that of the control
. (tab. 3).
Tab. 3. Average ± SD blood plasma concentration of pseu-


















* P < 0.05













































































The relationship between the expansion of examined
lung, gastric, and large intestine cancers and plasma
pseudouridine concentrations is presented in figure 4.
In the case of large intestine cancer (adenocarcinoma
of the colon and adenocarcinoma of the rectum) only
three patients (two with primary focus and one with
dissemination) had plasma pseudouridine concentra-
tions within control values (mean ± SD). In patients
with lung cancer an evident increase of plasma pseu-
douridine concentrations was seen only during dis-
semination. A relatively low response, independent of
disease progression, was observed in patients with

























Fig. 4. The relationship between expansion of malignant
growth and blood plasma pseudouridine concentration
in patients with carcinoma of the lung x, carcinoma of
the gaster A, and carconima of large intestine ·.
Discussion
The mean physiological concentration of pseudouri-
dine in blood plasma (tab. 2) is similar to that ob-
served in serum by Russo et al. (17) (2.48 μπιοί · ί"1)
and by Topp et al. (25) (2.76 μήιοί - Γ1)- A significant
positive correlation between the age of healthy adults
and plasma pseudouridine concentration was found
(fig. 2). A similar relationship was observed by Tritsch
et al. (26) for urinary pseudouridine concentrations,
rising by 5.9 mmol · mol"1 creatinine per decade. A
comparative analysis of serum pseudouridine concen-
tration, performed by Salvatore et al. (27) indicates
that practically all the data collected with the various
procedures agree within quite narrow limits. Rising
plasma pseudouridine concentrations in healthy
adults in our studies (fig. 2) may reflect an age-related
increase in the catabolism of whole-body rRNA
+ tRNA and/or renal insufficiency. The advantage
of the applied HPLC method is a simultaneous de-
termination of pseudouridine and creatinine (fig. 1),
and thus the possibility of a direct calculation of
plasma pseudouridine in relation to the creatinine
concentrations. Such an expression of the pseudour-
idine concentration takes into account changes in
dilution of blood plasma resulting from an increased
or decreased supply of water (e. g. absorption from
the gastrointestinal tract, parenteral infusions) and
impaired kidney function. Our recent study (28)
showed that pseudouridine accumulates markedly in
blood plasma (25 times higher concentration than
physiological) in patients with chronic renal failure.
Among examined purines and pyrimidines, pseudour-
idine had the lowest efficiency of haermodialysis (44%)
and the longest t1/2 (relative to-creatinine) in plasma.
In the present study, calculation of plasma pseudour-
idine in relation to creatinine concentration largely
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abolished the variability of pseudouridine with age.
According to Salvatore et al. (27) the serum "pseu-
douridine index" (pseudouridine: creatinine ratio) al-
most equalled the reference pseudburidine values for
normal subjects. In healthy subjects renal pseudouri-
dine clearance is lower than clearance of endogenous
creatinine (tab. 2), which indicates that pseudouridine
can be partially reabsorbed in renal tubules. The ratio
of pseudouridine vs. creatinine in blood plasma to
that in urine (1.48) was comparable to that reported
by Topp et al. (25). The method described by Kuo et
al. (15) allowed the separation and quantification of
other modified nucleosides in serum using reversed-
phase HPLC with diode-array measurement. The con-
centrations of other nucleosides in blood serum are
also consistently elevated in patients with malignant
proliferative diseases (15, 29), but it should be noted
that their blood plasma concentrations are 100 times
less than that of pseudouridine, and their concentra-
tions also display greater variability, due to non-
metabolic factors (19).
The relative independence of plasma pseudouridine
concentrations on non-metabolic factors, when cal-
culated per unit of creatinine, encouraged us to use
this form of pseudouridine expression in neoplastic
cases. In general, results of pseudouridine concentra-
tion in blood plasma expressed in absolute values
(μηιοί · I""1) correlate (r = 0.51) with relative values
(mmol -mol""1 creatinine), but not in all examined
patients. Among haematological neoplasms the high-
est concentration of pseudouridine was observed in
the plasma of patients suffering from multiple mye-
loma and chronic lymphocytic leukaemia (fig. 3). This
is in agreement with the findings of Sorensen et al.
(6), who demonstrated that urinary pseudouridine
excretion in multiple myeloma usually exceeds that in
other neoplasms, and there is a highly significant
linear trend towards a negative prognosis with a rising
concentration of urinary pseudouridine. It is interest-
ing that in mice carrying a transplantable myeloma
tumour no increase in the serum pseudouridine con-
centration was seen, despite the presence of a consid-
erable tumour burden (30). Our resultsMndicate that
the plasma pseudouridine concentration in patients
with multiple myeloma depends on tumour mass,
since the lowest concentration of this modified nucle-
oside was observed in remission and stage IA, and the
highest in stage IIIB of the disease (fig. 3).
There are several reports indicating increased urinary
pseudouridine excretion in children and adults with
different types of leukaemia (8 —11, 31, 32). We could
found no corresponding literature data for blood
plasma pseudouridine concentrations in chronic lym-
phocytic leukaemia. A single literature source (27)
reports that serum pseudouridine concentrations in
three patients with chronic lymphocytic leukaemia
ranged from 10.64 to 31.37 μιηοΐ · I"1. In contrast to
multiple myeloma, the plasma pseudouridine concen-
tration in chronic lymphocytic leukaemia does not
seem to be dependent on disease progression (fig. 3).
A considerable increase of the pseudouridine concen-
tration was observed both in early and advanced
stages of leukaemia. We suppose that the plasma
pseudouridine concentration might reflect prolifera-
tive activity of lymphoidal cells. However, a greater
number of cases should be examined, in order to
distinguish between various types of chronic lympho-
cytic leukaemia, characterized by more or less active
proliferation. It is interesting that chronic lymphocytic
leukaemia leads to a generally higher concentration
of pseudouridine in blood plasma than nor\-Hodgkin's
lymphoma, in spite of the clinically less dynamic pro-
gression of the disease. Our recent studies demon-
strated a significant increase in urinary pseudouridine
excretion in patients with multiple myeloma, chronic
lymphocytic leukaemia and non-Hodgkin's lym-
phoma, without significant changes in Hodgkin's dis-
ease and polycythaemia vera (33).
Rapid turnover of rRNA + tRNA is characteristic
of certain cancers of the gastrointestinal tract, espe-
cially large intestine adenocarcinomas.
However, in these cases the plasma pseudouridine
concentration was independent in disease progression,
since elevated concentrations of pseudouridine in
plasma were observed both in patients with early and
advances stages (fig. 4). A relatively low response was
observed in patients suffering from gastric and pan-
creatic adenocarcinoma. It is interesting that gastric
adenocarcinoma, in contrast to other cancers of the
gastrointestinal tract (e. g. large intestine adenocarci-
nomas), did not affect urinary pseudouridine excre-
tion independently of the stage of the disease (33). In
patients with lung cancer, the plasma pseudouridine
concentration seems to be dependent on dissemination
of the disease, and it increased in advanced cases with
metastases (fig. 4). The elevation of plasma pseu-
douridine concentration leads to increased urinary
pseudouridine excretion in patients with lung cancer
(33). McEntire et al. (21) showed that precise meas-
urement of an array of 29 nucleosides in serum with
subsequent data modelling may provide a clinically
useful approach to patient classification in diagnosis
of lung cancer and subsequent therapeutic monitor-
ing. The elevated plasma pseudouridine concentration
was also evident in all examined cases of cancer of
the urogenital system: cancer of the urinary bladder,
cancer of the kidney, cancer of the prostate, and
cancer of the testis. Recently, Rasmuson et al. (34)
Bur. J. Clin. Chem. CHn. Biochem. / Vol. 31,1993 / No. 11
770 Motyl et al.r Plasma pseudouridine in malignant proliferative diseases
demonstrated that increased urinary pseudouridine
excretion can be an independent prognostic factor in
renal cell carcinoma. The concentration of pseudour-
idine correlated to tumour grade and tumour size.
Survival time was also significantly reduced in pa-
tients with increased pseudouridine excretion.
In conclusion, we can say that the determination of
pseudouridine in blood plasma, particularly in rela-
tion to creatinine, is a valuable biochemical marker
of accelerated turnover rate of nucleic acids associated
with neoplastic growth. The most evident response in
blood plasma pseudouridine concentrations, noticed
in early stages of malignant growth, is characteristic
of patients with chronic lymphocytie leukaemia and
large intestine cancers. '
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